On June 26, 2025, Novo Nordisk announced a new collaboration with WeightWatchers to expand patient access to its blockbuster weight-loss drug, Wegovy, starting July 1. Cash-paying patients can access a month's supply of Wegovy for $299 through NovoCare Pharmacy via WeightWatchers.
This strategic partnership aims to provide a more streamlined experience for patients, combining FDA-approved medication with WeightWatchers' lifestyle support. The $299 price point is a significant discount, designed to make Wegovy more accessible and competitive against compounded alternatives.
The collaboration follows Novo Nordisk's termination of its partnership with Hims & Hers Health, signaling a shift in its telehealth strategy. Partnering with WeightWatchers, which no longer offers compounded semaglutide, aligns with Novo Nordisk's focus on authentic, FDA-approved products and holistic care models.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.